{"transactions":[{"id":941025,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T00:00:25.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":2.01,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-26-002973","document":"tm262917-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465926002973/tm262917-1_4seq1.xml","form_type":"4"}},{"id":1009621,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-04T01:00:23.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":false,"shares":1694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1694},"source":{"system":"sec-edgar","filing":"0001104659-25-105760","document":"tm2530101-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925105760/tm2530101-1_4seq1.xml","form_type":"4"}},{"id":1009620,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T01:00:23.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":true,"shares":1694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20317,"source":{"system":"sec-edgar","filing":"0001104659-25-105760","document":"tm2530101-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925105760/tm2530101-1_4seq1.xml","form_type":"4"}},{"id":1029299,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-10-01T23:00:03.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":false,"shares":1694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":1694,"derivative":{"underlying":"Common Stock","underlying_shares":1694},"source":{"system":"sec-edgar","filing":"0001104659-25-095739","document":"tm2527731-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925095739/tm2527731-1_4seq1.xml","form_type":"4"}},{"id":1029298,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T23:00:03.000Z","date":"2025-09-30","kind":"exercise","planned":false,"acquired":true,"shares":1694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":18623,"source":{"system":"sec-edgar","filing":"0001104659-25-095739","document":"tm2527731-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925095739/tm2527731-1_4seq1.xml","form_type":"4"}},{"id":1051442,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-09-02T23:00:14.000Z","date":"2025-08-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":3387,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-086528","document":"tm2524989-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925086528/tm2524989-1_4seq1.xml","form_type":"4"}},{"id":1051441,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:00:14.000Z","date":"2025-08-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":16930,"source":{"system":"sec-edgar","filing":"0001104659-25-086528","document":"tm2524989-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925086528/tm2524989-1_4seq1.xml","form_type":"4"}},{"id":1078408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-31T20:15:20.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":5080,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-072701","document":"tm2521524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925072701/tm2521524-1_4seq1.xml","form_type":"4"}},{"id":1078407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-31T20:15:20.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15237,"source":{"system":"sec-edgar","filing":"0001104659-25-072701","document":"tm2521524-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925072701/tm2521524-1_4seq1.xml","form_type":"4"}},{"id":1099290,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-30T20:30:31.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":6773,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-064148","document":"tm2519495-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925064148/tm2519495-1_4seq1.xml","form_type":"4"}},{"id":1099289,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T20:30:31.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":13544,"source":{"system":"sec-edgar","filing":"0001104659-25-064148","document":"tm2519495-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925064148/tm2519495-1_4seq1.xml","form_type":"4"}},{"id":1127693,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-02T23:10:11.000Z","date":"2025-05-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":8466,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-055610","document":"tm2516926-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925055610/tm2516926-1_4seq1.xml","form_type":"4"}},{"id":1127692,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:10:11.000Z","date":"2025-05-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":11851,"source":{"system":"sec-edgar","filing":"0001104659-25-055610","document":"tm2516926-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925055610/tm2516926-1_4seq1.xml","form_type":"4"}},{"id":1162482,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-05-01T23:23:09.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":10159,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-043628","document":"tm2513761-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925043628/tm2513761-1_4seq1.xml","form_type":"4"}},{"id":1162481,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T23:23:09.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10158,"source":{"system":"sec-edgar","filing":"0001104659-25-043628","document":"tm2513761-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925043628/tm2513761-1_4seq1.xml","form_type":"4"}},{"id":1186483,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-01T22:02:07.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":11852,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-030679","document":"tm2511097-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925030679/tm2511097-1_4seq1.xml","form_type":"4"}},{"id":1186482,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-01T22:02:07.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":8465,"source":{"system":"sec-edgar","filing":"0001104659-25-030679","document":"tm2511097-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925030679/tm2511097-1_4seq1.xml","form_type":"4"}},{"id":1228661,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:21:44.000Z","date":"2025-02-28","kind":"exercise","planned":false,"acquired":false,"shares":1693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last day of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last day of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":13545,"derivative":{"underlying":"Common Stock","underlying_shares":1693},"source":{"system":"sec-edgar","filing":"0001104659-25-020519","document":"tm258264-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925020519/tm258264-1_4seq1.xml","form_type":"4"}},{"id":1228660,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-05T02:21:44.000Z","date":"2025-02-28","kind":"exercise","planned":false,"acquired":true,"shares":1693,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6772,"source":{"system":"sec-edgar","filing":"0001104659-25-020519","document":"tm258264-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925020519/tm258264-1_4seq1.xml","form_type":"4"}},{"id":1284888,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-04T22:28:36.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":27089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":243810,"derivative":{"underlying":"Common Stock","underlying_shares":27089},"source":{"system":"sec-edgar","filing":"0001104659-25-009204","document":"tm255496-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925009204/tm255496-1_4seq1.xml","form_type":"4"}},{"id":1284887,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T22:28:36.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":27089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":81267,"source":{"system":"sec-edgar","filing":"0001104659-25-009204","document":"tm255496-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925009204/tm255496-1_4seq1.xml","form_type":"4"}},{"id":1314845,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-03T21:05:16.000Z","date":"2024-12-31","kind":"exercise","planned":true,"acquired":true,"shares":27089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":270899,"derivative":{"underlying":"Common Stock","underlying_shares":27089},"source":{"system":"sec-edgar","filing":"0001104659-25-000782","document":"tm251731-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925000782/tm251731-1_4seq1.xml","form_type":"4"}},{"id":1314844,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T21:05:16.000Z","date":"2024-12-31","kind":"exercise","planned":true,"acquired":true,"shares":27089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":54178,"source":{"system":"sec-edgar","filing":"0001104659-25-000782","document":"tm251731-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465925000782/tm251731-1_4seq1.xml","form_type":"4"}},{"id":1342970,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-12-04T21:05:10.000Z","date":"2024-11-30","kind":"exercise","planned":true,"acquired":false,"shares":27089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":297988,"derivative":{"underlying":"Common Stock","underlying_shares":27089},"source":{"system":"sec-edgar","filing":"0001104659-24-125506","document":"tm2430194-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465924125506/tm2430194-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-12-03"}},{"id":1342969,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:05:10.000Z","date":"2024-11-30","kind":"exercise","planned":true,"acquired":true,"shares":27089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":27089,"source":{"system":"sec-edgar","filing":"0001104659-24-125506","document":"tm2430194-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465924125506/tm2430194-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-12-03"}},{"id":1345073,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-12-03T21:05:17.000Z","date":"2024-11-21","kind":"grant","planned":true,"acquired":true,"shares":297988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":297998,"derivative":{"underlying":"Common Stock","underlying_shares":297988},"source":{"system":"sec-edgar","filing":"0001104659-24-125073","document":"tm2430075-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465924125073/tm2430075-1_4seq1.xml","form_type":"4"}},{"id":1345072,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-03T21:05:17.000Z","date":"2024-11-30","kind":"exercise","planned":true,"acquired":true,"shares":27089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":27089,"source":{"system":"sec-edgar","filing":"0001104659-24-125073","document":"tm2430075-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465924125073/tm2430075-1_4seq1.xml","form_type":"4"}},{"id":1352738,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-25T21:06:13.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":325077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period."}],"balance_after":325077,"derivative":{"underlying":"Common Stock","underlying_shares":325077},"source":{"system":"sec-edgar","filing":"0001104659-24-122570","document":"tm2429407-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000110465924122570/tm2429407-2_4seq1.xml","form_type":"4"}},{"id":4117339,"issuer":{"id":170596,"kind":"organization","name":"TERRAFORM GLOBAL, INC.","symbol":"GLBL"},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (Class A common stock)","published_at":"2018-01-03T02:26:08.000Z","date":"2017-12-28","kind":"other","acquired":false,"shares":12081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":12081},"source":{"system":"sec-edgar","filing":"0001620702-18-000012","document":"wf-form4_151494635471908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000162070218000012/wf-form4_151494635471908.xml","form_type":"4"}},{"id":4117338,"issuer":{"id":170596,"kind":"organization","name":"TERRAFORM GLOBAL, INC.","symbol":"GLBL"},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (Class A common stock)","published_at":"2018-01-03T02:26:08.000Z","date":"2017-12-28","kind":"disposition_to_issuer","acquired":false,"shares":55419,"price":5.1,"value":282636.9,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (\"Merger Sub\"), Merger Sub merged with and into TerraForm Global, Inc. (the \"Merger\"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (\"Merger Sub\"), Merger Sub merged with and into TerraForm Global, Inc. (the \"Merger\"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (\"Merger Sub\"), Merger Sub merged with and into TerraForm Global, Inc. (the \"Merger\"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings."}],"balance_after":12081,"derivative":{"underlying":"Class A Common Stock","underlying_shares":55419},"source":{"system":"sec-edgar","filing":"0001620702-18-000012","document":"wf-form4_151494635471908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000162070218000012/wf-form4_151494635471908.xml","form_type":"4"}},{"id":4240196,"issuer":{"id":170596,"kind":"organization","name":"TERRAFORM GLOBAL, INC.","symbol":"GLBL"},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (Class A common stock)","published_at":"2017-08-08T23:01:17.000Z","date":"2017-08-04","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the \"Brookfield Merger Agreement\") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The \"Prorated Vesting Percentage\" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the \"Brookfield Merger Agreement\") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The \"Prorated Vesting Percentage\" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the \"Brookfield Merger Agreement\") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The \"Prorated Vesting Percentage\" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%."}],"balance_after":67500,"derivative":{"underlying":"Class A Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001620702-17-000079","document":"wf-form4_150223326388744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000162070217000079/wf-form4_150223326388744.xml","form_type":"4"}},{"id":4491164,"issuer":{"id":170596,"kind":"organization","name":"TERRAFORM GLOBAL, INC.","symbol":"GLBL"},"owners":[{"id":58902,"kind":"person","name":"MACK DAVID J.","position":1,"cik":"0001694466","reported_name":"MACK DAVID J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units (Class A common stock)","published_at":"2017-01-13T22:38:25.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement."}],"balance_after":37500,"derivative":{"underlying":"Class A Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001620702-17-000008","document":"wf-form4_148434709333117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694466/000162070217000008/wf-form4_148434709333117.xml","form_type":"4"}}]}